Skip to main content
Premium Trial:

Request an Annual Quote

Saladax Signs on InyDia Labs to Distribute My5-FU in Spain, Portugal

NEW YORK (GenomeWeb News) – Saladax today announced a deal with InyDia Labs for the distribution of the My5-FU test in Spain and Portugal.

Saladax's My5-FU test measures levels of the oncology drug 5-fluorouracil, or 5-FU, in the blood of cancer patients, and the deal with InyDia makes it the exclusive provider of My5-FU test kits in the two countries.

Financial terms of the deal were not disclosed.

Based in Madrid, InyDia specializes in the production of in vitro diagnostic reagents and instruments, such as array readers and liquid handling platforms. It also offers personalized medicine products from other manufacturers.

Saladax is based in Bethlehem, Penn., and last month said it was partnering with the Central European Society for Anticancer Drug Research to study metastatic colorectal cancer patients treated with 5-FU using the My5-FU technology. The company also announced a distribution deal for the test covering Poland and Italy in December.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.